Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides

Antisense oligonucleotides (ASOs) designed to lower prion protein (PrP) expression in the brain through RNase H1-mediated degradation of PrP RNA are in development as prion disease therapeutics. ASOs were previously reported to sequence-independently interact with PrP and inhibit prion accumulation...

Descripción completa

Detalles Bibliográficos
Autores principales: Reidenbach, Andrew G., Minikel, Eric Vallabh, Zhao, Hien T., Guzman, Stacy G., Leed, Alison J., Mesleh, Michael F., Kordasiewicz, Holly B., Schreiber, Stuart L., Vallabh, Sonia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022474/
https://www.ncbi.nlm.nih.gov/pubmed/31861275
http://dx.doi.org/10.3390/biom10010001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022474/
https://www.ncbi.nlm.nih.gov/pubmed/31861275
http://dx.doi.org/10.3390/biom10010001

Ejemplares similares